Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Researchers conducted the IMPROVE trial to evaluate whether a 3-week pause in BTK inhibitor use would improve immunity after COVID-19 booster vaccination without negatively affecting disease control ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...